Biopharmaceuticals have transformed modern therapeutics by offering highly specific and effective treatment options for complex and chronic diseases such as cancer, autoimmune disorders, and metabolic conditions. Derived from living systems, these biologics include monoclonal antibodies, recombinant proteins, vaccines, and gene therapies, characterized by their structural complexity and sensitivity to manufacturing conditions. However, the high cost of biologics has limited patient accessibility, prompting the development of biosimilars—biological products that are highly similar to approved reference products in terms of quality, safety, and efficacy. The development of biosimilars involves rigorous analytical characterization, comparability studies, and clinical evaluations to ensure therapeutic equivalence while addressing immunogenicity concerns. Despite their potential to reduce healthcare costs and expand treatment access, biosimilars face significant challenges including complex manufacturing processes, regulatory hurdles, intellectual property issues, and market acceptance barriers. Regulatory agencies such as the FDA, EMA, and CDSCO have established stringent guidelines to ensure the quality and safety of both biopharmaceuticals and biosimilars. This review provides a comprehensive overview of the development processes, scientific and regulatory challenges, and future perspectives associated with biopharmaceuticals and biosimilars, highlighting their critical role in advancing global healthcare.